New research published in Annals of Rheumatic Diseases and Hypertension examined the impact medications for different non-cardiovascular conditions can have on a patient's heart health.

The single-dose gene therapy can help patients reduce their risk of bleeding events and discontinue factor IX prophylaxis therapy.

“There is a crucial need to develop synthetic vascular graft materials that will increase the rate of long-term functions,” one researcher said. Could materials derived from seaweed help fill that need?

Watch our exclusive interview, recorded live at the AHA Scientific Sessions 2022 conference, with three investigators from the BEST-CLI trial. 

A photo essay from the American Heart Association (AHA) 2022 Scientific Sessions Nov. 5-7 in Chicago.

Two late-breaking clinical trials presented at the VIVA Foundation’s VIVA22 conference in Las Vegas highlighted the impact drug-coated balloons can make on patient outcomes.